Organix

Organix is a well-established, private contract chemistry CRO that has served the pharmaceutical and biotech R&D sector for nearly three decades. It differentiates itself through specialized expertise in complex molecule synthesis, including lipids and oligonucleotides critical for modern drug modalities like mRNA and gene therapies, and operates a significant, purpose-built facility. As part of the Symeres family, it benefits from broader network resources while maintaining a focused 'lab next door' service model for its US clientele. The company is revenue-generating, deriving income from fee-for-service contracts, custom synthesis projects, and the sale of research chemicals.

Integrated contract chemistry services platform specializing in custom synthesis (including lipids, oligonucleotides, polymers), analytical characterization, and GMP manufacturing, supported by a custom-built 50,000 sq ft facility.

Organix competes in the fragmented chemistry CRO market against large global players (e.g., Labcorp, Eurofins), mid-sized specialized CROs, and small boutique firms. Its differentiation lies in its deep expertise in complex chemistries like lipids, its substantial US-based facility, and its long operational history, though it faces constant pressure on pricing and service speed.